Evidence map›Paper›PMID 41421534›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026

Synergistic venetoclax and anti-CD3 therapy for control of alloreactive response in hematopoietic stem cell transplantation.

Bettina P Iliopoulou, Shiva Pathak, Blake Mosher, Levon Witherspoon, Alexandra Wells, Cameron S Bader, Pin-I Chen, Nadine Nagy, Alejandro Villar-Prados, Kent Jensen and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bettina P IliopoulouDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA; Cellular Immune Tolerance Program, Stanford University School of Medicine, Stanford, California, USA.
Shiva PathakDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA; Cellular Immune Tolerance Program, Stanford University School of Medicine, Stanford, California, USA; Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, California, USA.
Blake MosherDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA.
Levon WitherspoonDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA.
Alexandra WellsDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA.
Cameron S BaderDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA; Cellular Immune Tolerance Program, Stanford University School of Medicine, Stanford, California, USA.
Pin-I ChenDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA; Cellular Immune Tolerance Program, Stanford University School of Medicine, Stanford, California, USA.
Nadine NagyDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA; Cellular Immune Tolerance Program, Stanford University School of Medicine, Stanford, California, USA; Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, California, USA.
Alejandro Villar-PradosDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA.
Kent JensenDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA; Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, California, USA.
Everett H MeyerDivision of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California, USA; Cellular Immune Tolerance Program, Stanford University School of Medicine, Stanford, California, USA; Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, California, USA. Electronic address: evmeyer@stanford.edu.

Funding

High-resolution tracking of T cell differentiation to predict and control alloreactive diseaseK99HL179392 · NHLBI · STANFORD UNIVERSITY · PI Cameron Scott Bader · 2025 to 2026
$262k
NHLBI NIH HHS K99 HL179392
6 · The paper itself

Abstract

T cell-based immunotherapies are effective for treating hematological malignancies and promoting lifelong graft tolerance after solid organ transplantation. Recipient preconditioning resulting in profound lymphodepletion is a key to preventing graft rejection and maximizing T cell engraftment. The 2 standard lymphodepleting agents, antithymocyte globulin and cyclophosphamide chemotherapy, are associated with major adverse effects in patients. This research investigates a new therapeutic approach that combines anti-CD3 (aCD3) therapy with venetoclax, as a BCL-2 inhibitor and T cell immunoglobulin and mucin 1 blockade to achieve optimal T cell lymphodepletion and immune tolerance in preclinical hematopoietic stem cell transplantation models. This conditioning regimen strongly induces T cell apoptosis, particularly in naïve and central memory CD8

Indexed as

Bridged Bicyclo Compounds, HeterocyclicCD3 ComplexGraft RejectionGraft vs Host DiseaseHematopoietic Stem Cell TransplantationIslets of Langerhans TransplantationSulfonamidesTransplantation ConditioningAnimalsDrug SynergismGraft SurvivalHumansMiceMice, Inbred C57BLTransplantation ToleranceBridged Bicyclo Compounds, HeterocyclicCD3 ComplexSulfonamidesvenetoclaxaCD3allograftGVHDtolerancetransplantationvenetoclax

Identifiers

PMID41421534
PMCPMC13245109

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.